Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
761-780 of 991 trials

Ghrelin for Acute Ischemic Stroke Treatment

We are studying whether ghrelin can improve recovery in patients with acute ischemic stroke treated with endovascular thrombectomy. The trial will also assess its effects on overall health and safety over several days.

Ischemic Stroke1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology

Functional Dyspepsia: Rikkunshito Study

We are investigating whether Rikkunshito can help relieve symptoms in patients with functional dyspepsia. The study also looks at how it may affect the digestive lining and overall gut function.

Functional Dyspepsia3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Non-Small Cell Lung Cancer: BNT327 with Chemotherapy

We are studying the safety and effectiveness of BNT327, an investigational therapy, combined with chemotherapy for patients with non-small cell lung cancer. This trial compares it to standard treatments to see which works better.

Non-small cell lung cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Pulmonary Hypertension: Sotatercept Study

We are investigating the safety and effects of sotatercept in individuals with pulmonary hypertension due to heart failure. This study aims to understand how well the treatment works over time.

Pulmonary Hypertension>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Chronic Infection in Hip and Knee Implants: 68Ga PET/CT Study

We are investigating whether a new imaging technique can accurately diagnose chronic infections in artificial hip and knee joints. This study compares its effectiveness to other existing diagnostic methods.

Prosthetic Joint Infection>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyOtolaryngology

Tarlatamab for Advanced Small-Cell Lung Cancer

We are studying a new treatment for patients with metastatic or locally advanced small-cell lung cancer and other neuroendocrine carcinomas. The goal is to see how well it works and to understand its safety.

Metastatic Small Cell Lung Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Vosoritide for Growth Issues in Children

We are studying a new treatment called vosoritide for children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome who haven't responded well to standard growth hormone therapy. The goal is to see if it helps improve their growth and is safe to use.

Turner SyndromeShort Stature Homeobox Gene MutationNoonan Syndrome1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyPediatrics

Chickenpox Vaccine Safety Study for Young Children

We are evaluating the safety of a new chickenpox vaccine for healthy children aged 12 to 15 months. This study compares it with an existing vaccine when given with other routine immunizations.

Chickenpox6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Chickenpox Vaccine Study for Children Aged 12 to 15 Months

We are evaluating a new chickenpox vaccine to see how well it works and its safety compared to the standard Varivax vaccine in healthy children. This study aims to ensure that the new vaccine provides a strong immune response.

Chickenpox6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Clindamycin for Infections: Impact of Rifampicin and Obesity

We are studying how body weight and the antibiotic rifampicin affect the effectiveness of clindamycin in treating infections. This research may help improve treatment strategies for patients with varying body types.

Hidradenitis SuppurativaProsthetic Joint InfectionsFracture Related Infections≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Small Cell Lung Cancer: Sacituzumab Govitecan vs. Standard Care

We are studying a new treatment called sacituzumab govitecan for patients with previously treated extensive stage small cell lung cancer. The goal is to see if it works better and is safer than current standard treatments.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: 89Zr-Df-crefmirlimab Imaging Study

We are studying a new imaging method to see how well it shows cancer cells in patients with advanced solid tumors. This may help us understand treatment responses and immune cell activity better.

Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Posttraumatic Headache: Botulinum Toxin A Study

We are investigating whether botulinum toxin A can safely reduce the number of headache days for individuals with posttraumatic headaches. The study also looks at biological markers to see if they can predict treatment success.

Post-Traumatic Headache3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Chronic Lung Disease in Premature Babies: OHB-607 Study

We are testing a new drug to see if it helps reduce lung disease in extremely premature infants compared to standard care. The study aims to improve their overall health and development.

Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Myelofibrosis: Study of Pacritinib vs. Standard Treatment

We are investigating whether pacritinib can better reduce spleen size and improve symptoms in patients with myelofibrosis. This trial is for those with severe low platelet counts and compares pacritinib to physician's choice of therapy.

Post-Polycythaemia Vera MyelofibrosisPrimary MyelofibrosisPost-Essential Thrombocythaemia Myelofibrosis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Hidradenitis Suppurativa: Brensocatib Study

We are testing a new medication, brensocatib, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it is more effective than a placebo in improving symptoms.

Hidradenitis Suppurativa1-2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Dystonia: Botulinum Toxin for Arm Tremors

We are exploring how different tests and imaging techniques can help determine the effectiveness of botulinum toxin for treating arm tremors in people with dystonia. This study aims to improve treatment options for those affected.

Dystonic Tremor Syndrome6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Rheumatoid Arthritis: IMVT-1402 Treatment Study

We are evaluating a new treatment for adults with difficult-to-treat rheumatoid arthritis. The study aims to see if it helps improve symptoms compared to a placebo.

ACPA-Positive Rheumatoid Arthritis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Generalized Myasthenia Gravis: IMVT-1402 Study

We are testing a new treatment for people with mild to severe generalized myasthenia gravis. The study aims to see if it can improve muscle strength and reduce symptoms.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)Investigational MedicinesCost ReimbursementNeurology

Post-Surgical Hypoparathyroidism: Indapamide Treatment

We are studying whether daily Indapamide can help manage calcium levels in patients with post-surgical hypoparathyroidism. This trial will also look at the safety of the treatment and its effects on urinary calcium excretion.

Hypoparathyroidism≤3 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementEndocrinologyInternal Medicine